On January 18th, Celgene announced a partnership with Kyn Therapeutics, a startup that is committed to developing immune systems against cancer. Kyn is an investment by Atlas Venture and OrbiMed and is headquartered in Boston. Celgene will pay Kyn a down payment of $80 million and an undisclosed equity… Continue Reading Celgene’s heavy trading

  B vitamins are all coenzymes involved in the metabolism of important substances such as sugar, fat and protein, and are indispensable water-soluble vitamins for maintaining normal functions of the human body. B vitamins are easily destroyed in an alkaline environment, and the human body cannot manufacture and synthesize by… Continue Reading Summary of the efficacy of B vitamins

  In recent years, the number of new drugs approved by the FDA has reached record highs. With this situation, the pricing of specialty drugs is getting higher and higher, and the prices of some new technology therapies that have not yet been approved are even more jaw-dropping. According to… Continue Reading The 20 most expensive drugs in the US pharmacy retail price in 2018

  What role will technology play in the healthcare industry in 2019? For venture capitalists and others interested in the medical industry, it is critical to be able to predict the direction of industry innovation more accurately than others. Recently, MedCity News has predicted five major innovation trends affecting the… Continue Reading These 5 major innovation trends will affect the medical and health industry in 2019.

  In 2006, Stanford University professor Andrew Z. Fire and University of Massachusetts Medical Professor Craigc. Mello won the 2006 Nobel Prize in Physiology/Medical for discovering RNA interference (RNAi) and their outstanding contributions in the field of gene silencing. At the time of the award, they predicted that the application… Continue Reading 2018 Top Ten RNA Therapy Company, the first place is not Moderna?

  Two years ago, the University of Basel’s Don Benjanmin research team published an article in the journal Science Advance, saying that the antihypertensive drug syrosingopine (silosepine) significantly enhanced the anti-tumor efficacy of metformin, causing the medical community. Extensive discussion: Metformin plus carbazone is an anticancer drug? But the research… Continue Reading Metformin anticancer mechanism

  EvaluatePharma recently released the “EP Vantage 2019 Preview” report, which uses the net present value method (NPV) to evaluate the market potential of new drugs in the world. Regarding the net present value, you can simply understand “how much is the value of a new drug asset at a… Continue Reading Outlook 2019: The world’s most valuable new drug TOP20

  Recently, the international authoritative medical journal BMJ published a highly subversive heavyweight paper, which caused great sensation in the medical field. A large cohort study based on nearly a million people showed that the use of ACEI-type antihypertensive drugs increased the overall risk of lung cancer by 14% compared… Continue Reading A large follow-up study of 1 million people revealed that the classic antihypertensive drug ACEIs took more than 10 years, and the risk of lung cancer increased by 31%.

  In the field of Alzheimer’s disease, no company has suffered more defeat than Lilly. However, this does not prevent the pharmaceutical giant from betting on Alzheimer’s disease assets again and signing a $2 billion deal. Eli Lilly’s core asset, developed in collaboration with AC Immune, is a drug code-named… Continue Reading Lilly will gamble on Alzheimer’s disease and collaborate to develop a preclinical Tau protein-targeted drug for $2 billion.

  On December 12, Janssen announced the 48-week results of the head-to-head PKECLIPSE Phase III study of Tremfya (guselkumab) and Cosentyx (secukinumab) for the treatment of moderate to severe plaque psoriasis. In the Tremfya treatment group, the psoriasis area and severity index improved by more than 90% (PASI 90, primary… Continue Reading Johnson & Johnson’s new psoriasis PK wins, Novartis Cosentyx is counterattacked